|
- Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
Adstiladrin is used to treat adult patients with high-risk, non-muscle invasive bladder cancer (NMIBC) that hasn't responded to the standard treatment, Bacillus Calmette-Guérin (BCG)
- ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
- Package Insert - ADSTILADRIN
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy designed to deliver a copy of a gene encoding a human interferon-alfa 2b (IFNα2b) to the bladder urothelium
- Nadofaragene firadenovec - Wikipedia
Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer [1][3][4] It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy
- ADSTILADRIN- nadofaragene firadenovec-vncg suspension - DailyMed
ADSTILADRIN is a sterile, clear to opalescent suspension for intravesical instillation, supplied as single-use vials ADSTILADRIN is provided in a carton containing four (4) vials
- More about ADSTILADRIN® – Bladder Cancer Advocacy Network
ADSTILADRIN is a localized gene therapy designed to help the immune system fight NMIBC directly within the bladder Administered once every 3 months, it works as a monotherapy, meaning it does not require combination with other medications to be effective
- Package Insert - ADSTILADRIN
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
- HOW TO USE ADSTILADRIN
Retain ADSTILADRIN in the bladder for 1 hour after administration During the 1-hour dwell time, the patient should be repositioned approximately every 15 minutes from left to right and back to abdomen to maximize bladder surface exposure
|
|
|